Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cirmtuzumab in relapsed or refractory CLL
NCT02222688Phase 1Completed
- Start
- Aug 2014
- Primary completion
- Oct 2017
- Countries
- 1
01
Overview
Phase 1, open-label trial of cirmtuzumab in chronic lymphocytic leukemia (CLL). Started Aug 2014; status: completed.
02
Drugs
cirmtuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02222688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02222688.